Metastatic Basal Cell Carcinoma of the Skin

Abstract

Background: The literature on metastatic basal cell carcinoma (mBCC) reveals the rarity of this condition, which emerges from the more prevalent basal cell carcinoma (BCC), accounting for about 80% of nonmelanoma skin cancers. Literature Review: Risk factors for mBCC include age, skin type, prior skin damage, and tumor characteristics, which significantly influence prognosis ((Aditya & Rattan, 2013); (Lance Cowey, 2013)). Once metastasized, BCC is associated with a poor prognosis, with surgical options often becoming limited as the disease progresses ((Lance Cowey, 2013)). The emergence of targeted therapies, particularly vismodegib, which inhibits the Hedgehog signaling pathway, marks a significant advancement in treatment options for advanced and metastatic cases ((Berrada et al., 2014); (Hoashi et al., 2022)). These therapies provide alternatives for patients unsuitable for surgery and represent a shift towards more personalized treatment approaches ((Lance Cowey, 2013)) The literature also emphasizes the importance of accurate diagnosis, particularly in atypical presentations where primary BCC may mimic metastatic disease ((Haskell Hanisch et al., 2023)). Histopathological evaluation remains crucial in differentiating between these forms, as misdiagnosis can lead to inappropriate treatment strategies ((Haskell Hanisch et al., 2023)).. Conclusions: In conclusion, the body of literature on mBCC highlights its rarity and the complexities involved in its diagnosis and treatment. The low incidence of metastasis, coupled with the challenges posed by advanced forms of BCC, underscores the necessity for ongoing research into effective treatment modalities and the development of targeted therapies. Furthermore, understanding the risk factors and clinical characteristics associated with mBCC is essential for improving patient outcomes and guiding clinical management.